1. Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis
- Author
-
Marti, Zoe, Ruder, Josefine, Thomas, Olivia G., Bronge, Mattias, Lorenzo, de la Parra Soto, Gronlund, Hans, Olsson, Tomas, Martin, Roland, Marti, Zoe, Ruder, Josefine, Thomas, Olivia G., Bronge, Mattias, Lorenzo, de la Parra Soto, Gronlund, Hans, Olsson, Tomas, and Martin, Roland
- Abstract
Multiple sclerosis (MS) is a prototypical autoimmune disease of the central nervous system (CNS). In addition to CD4(+) T cells, memory B cells are now recognized as a critical cell type in the disease. This is underlined by the fact that the best-characterized environmental risk factor for MS is the Epstein-Barr virus (EBV), which can infect and persist in memory B cells throughout life. Several studies have identified changes in anti-EBV immunity in patients with MS. Examples include elevated titers of anti-EBV nuclear antigen 1 (EBNA1) antibodies, interactions of these with the MS-associated HLA-DR15 haplotype, and molecular mimicry with MS autoantigens like myelin basic protein (MBP), anoctamin-2 (ANO2), glial cell adhesion molecule (GlialCAM), and alpha-crystallin B (CRYAB). In this study, we employ a simple in vitro assay to examine the memory B cell antibody repertoire in MS patients and healthy controls. We replicate previous serological data from MS patients demonstrating an increased secretion of anti-EBNA1(380-641) IgG in cell culture supernatants, as well as a positive correlation of these levels with autoantibodies against GlialCAM(262-416) and ANO2(1-275). For EBNA1(380-641) and ANO2(1-275), we provide additional evidence suggesting antibody cross-reactivity between the two targets. Further, we show that two efficacious MS treatments - natalizumab (NAT) and autologous hematopoietic stem cell transplantation (aHSCT) - are associated with distinct changes in the EBNA1-directed B cell response and that these alterations can be attributed to the unique mechanisms of action of these therapies. Using an in vitro system, our study confirms MS-associated changes in the anti-EBNA1 memory B cell response, EBNA1(380-641) antibody cross-reactivity with ANO2(1-275,) and reveals treatment-associated changes in the immunoglobulin repertoire in MS.
- Published
- 2024
- Full Text
- View/download PDF